REQUEST A DEMO
Total
USD $0.00
Search more companies

ASLAN Pharmaceuticals Limited (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing | Research and Development in the Physical, Engineering, and Life Sciences
Full name: ASLAN Pharmaceuticals Limited Profile Updated: October 12, 2022
Buy our report for this company USD 19.99 Most recent financial data: 2019 Available in: English & Chinese Download a sample report

ASLAN Pharmaceuticals Limited is a biotechnology company that develops a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. The company was founded in 2014 and is based in Singapore.

Headquarters
37/F, No.100, Songren Rd, Xinyi Dist., Taipei
Taipei City; Taipei City;

Contact Details: Purchase the ASLAN Pharmaceuticals Limited report to view the information.

Website: http://www.aslanpharma.com/zh/

Basic Information
Total Employees:
Purchase the ASLAN Pharmaceuticals Limited report to view the information.
Outstanding Shares:
Purchase the ASLAN Pharmaceuticals Limited report to view the information.
Financial Auditors:
Purchase the ASLAN Pharmaceuticals Limited report to view the information.
Incorporation Date:
June 23, 2014
Key Executives
Purchase this report to view the information.
Chairman of the Board of Directors
Purchase this report to view the information.
President
Purchase this report to view the information.
Spokesperson
Ownership Details
Purchase this report to view the information.
4.65%
Purchase this report to view the information.
3.97%
Purchase this report to view the information.
1.76%
Purchase this report to view the information.
0.23%
Purchase this report to view the information.
Subsidiaries
ASLAN Pharmaceuticals Pte. Ltd
100%
Company Performance
Financial values in the chart are available after ASLAN Pharmaceuticals Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
39.87%
EBITDA
43.69%
Net Profit (Loss) for the Period
42.36%
Total assets
-64.14%
Total equity
N/A
Return on Equity (ROE)
N/A
Debt to Equity Ratio
N/A
Quick Ratio
0.69%
Cash Ratio
0.65%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?